ClinicalTrials.gg
CompletedNCT06490328Updated Aug 14, 2026

Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer

A Phase 3 interventional study of DKF-MA102 in Advanced Prostate Cancer, sponsored by Dongkook Pharmaceutical Co., Ltd.. Completed at 8 sites in South Korea. Open to male participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by Dongkook Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
161
Allocation
Not applicable
Ages
19 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing leuprolide in Prostatic Neoplasms — 9 open to participants now, 16 under way, 6 of them phase 3. Leuprolide · Prostatic Neoplasms.

Enrollment
17th of 69
161 · median 77
Started
2024
with 3 others
Phase 3
26 of 70
3 open now
Registered
64th of 70
by date

Among the 70 studies testing leuprolide in Prostatic Neoplasms, this one is the 17th largest by enrollment of the 69 interventional ones that give a count, is one of 4 that started in 2024, is one of 26 in phase 3, and was the 64th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

9 of the 70 studies testing leuprolide in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About leuprolide

Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 19 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing leuprolide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

A phase 3, multi-center, single-group, open-label study to evaluate the efficacy and safety of DKF-MA102 in patients with prostate cancer.

Read the detailed description

This study is conducted to confirm the pharmacodynamic effects, efficacy, and safety of DKF-MA102 in prostate cancer patients by measuring the changes in serum testosterone levels.

03

Conditions studied

  • Advanced Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult male aged 19 or older
  2. or cytologically-confirmed prostate cancer
  3. Serum testosterone level >150 ng/dL
  4. PS grade ≤ 2
  5. of at least 1 year

Exclusion criteria

Exclusion Criteria:

  1. History of surgical procedures such as testicular resection, adrenal resection, and pituitary resection
  2. History of hormone therapy
  3. History of 5α-reductase inhibitor
  4. History of radical radiation therapy
  5. History of male hormone block therapy
  6. Severe liver failure
  7. Serum creatinine ≥1.5 times the
  8. Hormone-independent prostate cancer
  9. Diagnosed pituitary adenoma
  10. or spinal cord compression
  11. Requires prostatectomy, radiation therapy, chemotherapy, and anti-androgen therapy during the clinical trial period
  12. Urinary tract obstruction
  13. Cardiovascular disease
  14. Significant impairments in the digestive system, respiratory system, endocrine system, and central nervous system
  15. Uncontrolled diabetes
  16. Allergic reaction or to any ingredient of the product or to a synthetic GnRH or GnRH analogs
  17. Severe asthma, severe vascular edema, and severe hives
  18. Significant infection
  19. Lack of self-determination due to psychiatric illness
  20. Participating in another interventional clinical trial
  21. Pregnant or unwilling to use medically approved
  22. Deemed inappropriate to participate in this clinical trial by the investigator
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
161 participants (actual)

Study arms

  • Experimental
    DKF-MA102

    Leuprorelin acetate

    Drug: DKF-MA102

Interventions

  • Administered twice at 12-week intervals

    Also known as: Leuprorelin acetate

06

What researchers measure

Primary outcomes

  1. Percentage of participants

    Percentage of participants with testosterone suppression(≤ 50ng/dL) at Week 4

    Time frame: Week 4

  2. Percentage of participants

    Percentage of participants with testosterone suppression(≤ 50ng/dL) from Week 4 to Week 24

    Time frame: Week 24

Secondary outcomes

  1. Serum luteinizing hormone(LH) levels

    Changes in serum luteinizing hormone(LH) levels from baseline to Weeks 4, 12 and 24

    Time frame: Week 24

  2. Serum prostate specific antigens(PSA)

    Changes in serum prostate specific antigens(PSA) from baseline to Weeks 4, 12 and 24

    Time frame: Week 24

  3. Percentage of participants

    Percentage of participants with testosterone suppression(≤ 20ng/dL) from Week 4 to Week 24

    Time frame: Week 24

  4. Quality of life(FACT-P)

    Comparative evaluation of quality of life(FACT-P) of subjects from baseline to Weeks 4, 12 and 24

    Time frame: Week 24

07

Study locations

8 sites
  • National Cancer Center
    Gyeonggi-do, South Korea
  • Seoul National University Bundang Hospital
    Gyeonggi-do, South Korea
  • Asan Medical Center
    Seoul, South Korea
  • Ewha Womans University mokdong Hospital
    Seoul, South Korea
  • Gangnam Severance Hospital, Yonsei University College of Medicine
    Seoul, South Korea
  • Samsung Medical Center
    Seoul, South Korea
  • Seoul National University Hospital
    Seoul, South Korea
  • Seoul Saint. Mary's Hospital
    Seoul, South Korea
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be made publicly available.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Jan 2026, 19 months.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 19 months is below that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2024
First posted
Jul 8, 2024
StartActual
May 30, 2024
Primary completionActual
Jan 21, 2026
CompletionActual
Mar 9, 2026
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06490328
Lead sponsor
Dongkook Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Jul 8, 2024
Start date
May 30, 2024
Primary completion
Jan 21, 2026
Completion
Mar 9, 2026
Last update
Aug 14, 2026

Study contacts

Choung-Soo Kim, M.D.,Ph.D
principal investigator · Ewha Womans University Mokdong Hospital
Jae Young Joung, M.D.,Ph.D
principal investigator · Center for Prostate Cancer, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do 10408, Republic of Korea
Sung Kyu Hong, M.D.,Ph.D
principal investigator · Department of Urology, Seoul National University Bundang Hospital, 82, Gumi-ro, 173 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do 463-707, Korea
Seong Soo Jeon, M.D.,Ph.D
principal investigator · Department of Urology, Samsung Medical Center, 81, Irwon-ro, Gangnam-gu, Seoul 135-710, Korea
Cheol Kwak, M.D.,Ph.D
principal investigator · Department of Urology, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
Kyo Chul Koo, M.D.,Ph.D
principal investigator · Department of Urology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
Bumjin Lim, M.D.
principal investigator · Department of Urology, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea
Ji Youl Lee, M.D.,Ph.D
principal investigator · Department of Urology, Seoul Saint. Mary's Hospital, 222 Banpo-daero, Seocho-gu, Seoul 06591, South Korea

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leuprolide

Start the discussion